Ezrin and Alpha-smooth Muscle Actin Are Immunohistochemical Prognostic Markers in Conventional Osteosarcomas

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2007 Sep 6

PMID 17786474

Citations 24

Authors

Sebastien Salas

Catherine Bartoli

Jean-Laurent Deville

Jean Gaudart

Frederic Fina

Arlette Calisti

Gerard Bollini

Georges Curvale

Jean-Claude Gentet

Florence Duffaud

Dominique Figarella-Branger

Corinne Bouvier

Affiliations

Soon will be listed here.

Abstract

Ezrin is a cytoskeleton linker protein that is actively involved in the metastatic process of cancer cells. We have searched for a prognostic value of ezrin and some of its partners: alpha-smooth muscle actin and CD44H in 37 patients with an osteosarcoma. Automate immunohistochemistry (IHC) with anti-ezrin, alpha-smooth muscle actin and CD44H antibodies was performed in 66 specimens: 37 biopsies before chemotherapy, 16 resected tumours of "poor" responders and 13 metastases. The messenger RNA (mRNA) levels of ezrin of 13 frozen biopsies and 4 metastases were evaluated by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR). All results were correlated to the following clinical data. Ezrin expression by IHC was found in 62% of 37 biopsies in the different histological subtypes. A good correlation was found between positive or negative samples by IHC and mRNA levels. Ezrin expression was recorded in 84.5% of metastastic samples. The mean expression of ezrin was higher in metastases than biopsies (p = 0.024). In multivariate analysis, ezrin was an independent prognostic marker for event-free survival and overall survival (OS) with p < 0.001 and p = 0.003, respectively, and alpha-smooth muscle actin for OS only (p = 0.024). Our findings suggest that ezrin and alpha-smooth muscle actin are predictive IHC prognostic markers for patients with an osteosarcoma.

Citing Articles

Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma.

Lacinski R, Dziadowicz S, Melemai V, Fitzpatrick B, Pisquiy J, Heim T Bone Res. 2024; 12(1):55.

PMID: 39333065 PMC: 11436896. DOI: 10.1038/s41413-024-00359-z.

Immunophenotyping of an Unusual Mixed-Type Extraskeletal Osteosarcoma in a Dog.

Kim H, Kim H, Hwang H, Ahn J, Do S Vet Sci. 2021; 8(12).

PMID: 34941834 PMC: 8707392. DOI: 10.3390/vetsci8120307.

Knockdown of Ezrin inhibited migration and invasion of cervical cancer cells in vitro.

Xi M, Tang W Int J Immunopathol Pharmacol. 2020; 34:2058738420930899.

PMID: 32674647 PMC: 7370327. DOI: 10.1177/2058738420930899.

Overexpression of B7-H3 in α-SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas.

Zhan S, Liu Z, Zhang M, Guo T, Quan Q, Huang L Front Oncol. 2020; 9:1466.

PMID: 31998637 PMC: 6966326. DOI: 10.3389/fonc.2019.01466.

The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta-analysis.

Wang F, Yu T, Ma C, Zhang H, Zhang Z FEBS Open Bio. 2019; 9(10):1744-1755.

PMID: 31376222 PMC: 6768105. DOI: 10.1002/2211-5463.12713.

References

Link M, Goorin A, Miser A, Green A, Pratt C, Belasco J . The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314(25):1600-6. DOI: 10.1056/NEJM198606193142502. View

Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H . Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol. 1999; 125(11):646-52. DOI: 10.1007/s004320050329. View

Hasegawa T, Hirose T, Seki K, Hizawa K, Ishii S, Wakabayashi J . Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas. Cancer Detect Prev. 1997; 21(3):280-7. View

Martin T, Harrison G, Mansel R, Jiang W . The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 2003; 46(2):165-86. DOI: 10.1016/s1040-8428(02)00172-5. View

Yu Y, Khan J, Khanna C, Helman L, Meltzer P, Merlino G . Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004; 10(2):175-81. DOI: 10.1038/nm966. View

Saeter G, Alvegard T, Elomaa I, Stenwig A, Holmstrom T, SOLHEIM O . Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991; 9(10):1766-75. DOI: 10.1200/JCO.1991.9.10.1766. View

Antonescu C, Erlandson R, Huvos A . Primary leiomyosarcoma of bone: a clinicopathologic, immunohistochemical, and ultrastructural study of 33 patients and a literature review. Am J Surg Pathol. 1997; 21(11):1281-94. DOI: 10.1097/00000478-199711000-00003. View

Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G . Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut. 2004; 53(2):235-40. PMC: 1774925. DOI: 10.1136/gut.2003.021238. View

Yamamura H, Yoshikawa H, Tatsuta M, Akedo H, Takahashi K . Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis. Int J Cancer. 1998; 79(3):245-50. DOI: 10.1002/(sici)1097-0215(19980619)79:3<245::aid-ijc6>3.0.co;2-p. View

10.

Wan X, Mendoza A, Khanna C, Helman L . Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005; 65(6):2406-11. DOI: 10.1158/0008-5472.CAN-04-3135. View

11.

Harris M, Gieser P, Goorin A, Ayala A, Shochat S, Ferguson W . Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol. 1998; 16(11):3641-8. DOI: 10.1200/JCO.1998.16.11.3641. View

12.

Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C . Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001; 61(9):3750-9. View

13.

Vaheri A, Carpen O, Heiska L, Helander T, Jaaskelainen J, Sainio M . The ezrin protein family: membrane-cytoskeleton interactions and disease associations. Curr Opin Cell Biol. 1997; 9(5):659-66. DOI: 10.1016/s0955-0674(97)80119-6. View

14.

Provisor A, Ettinger L, Nachman J, Krailo M, Makley J, Yunis E . Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15(1):76-84. DOI: 10.1200/JCO.1997.15.1.76. View

15.

Rosen G, Marcove R, Caparros B, Nirenberg A, Kosloff C, Huvos A . Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979; 43(6):2163-77. DOI: 10.1002/1097-0142(197906)43:6<2163::aid-cncr2820430602>3.0.co;2-s. View

16.

Weng W, Ahlen J, Astrom K, Lui W, Larsson C . Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 2005; 11(17):6198-204. DOI: 10.1158/1078-0432.CCR-05-0548. View

17.

Taylor W, IVINS J, Unni K, Beabout J, Golenzer H, Black L . Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst. 1989; 81(1):21-30. DOI: 10.1093/jnci/81.1.21. View

18.

Meyers P, Gorlick R . Osteosarcoma. Pediatr Clin North Am. 1997; 44(4):973-89. DOI: 10.1016/s0031-3955(05)70540-x. View

19.

Rocchi P, Muracciole X, Fina F, Mulholland D, Karsenty G, Palmari J . Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene. 2004; 23(56):9111-9. DOI: 10.1038/sj.onc.1208154. View

20.

Weber G, Bronson R, Ilagan J, Cantor H, Schmits R, Mak T . Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res. 2002; 62(8):2281-6. View